FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1799-1801 December 14, 2000 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Rai, K. R. PubMed Citation

Chronic lymphocytic leukemia (CLL), the most common form of leukemia in adults, is usually recognized first by the patient's primary care physician. When the patient has other medical problems — which is frequently the case, given that the median age at diagnosis is 64 years — the primary care physician collaborates with the hematologist or oncologist in treating the patient. It is often difficult to make decisions about therapy, which can involve subtle factors that are best understood by the patient's own doctor.

CLL most commonly arises from a malignant clone of B cells with a characteristic phenotype. It is . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Robak, T., Blonski, J. Z., Gora-Tybor, J., Jamroziak, K., Dwilewicz-Trojaczek, J., Tomaszewska, A., Konopka, L., Ceglarek, B., Dmoszynska, A., Kowal, M., Kloczko, J., Stella-Holowiecka, B., Sulek, K., Calbecka, M., Zawilska, K., Kuliczkowski, K., Skotnicki, A. B., Warzocha, K., Kasznicki, M., the Polish Leukemia Group (PALG CLL2), (2006). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108: 473-479 [Abstract] [Full Text]  
• Secchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M. G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A., Zauli, G. (2006). Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107: 4122-4129 [Abstract] [Full Text]  
• Secchiero, P., Barbarotto, E., Gonelli, A., Tiribelli, M., Zerbinati, C., Celeghini, C., Agostinelli, C., Pileri, S. A., Zauli, G. (2005). Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. Am. J. Pathol. 167: 1599-1607 [Abstract] [Full Text]  
• Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinkothe, T., Stutzer, H., Rech, J., Gramatzki, M., Aulitzky, W., Hasan, I., Josting, A., Hallek, M., Engert, A. (2005). Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial. JCO 23: 7024-7031 [Abstract] [Full Text]  
• Rassenti, L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J., Gribben, J. G., Neuberg, D. S., Flinn, I. W., Rai, K. R., Byrd, J. C., Kay, N. E., Greaves, A., Weiss, A., Kipps, T. J. (2004). ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia. NEJM 351: 893-901 [Abstract] [Full Text]  
• Wells, T., Kovacs, M. J (2003). Autoimmune Thrombocytopenia Due to Chronic Lymphocytic Leukemia Treated with Fludarabine. The Annals of Pharmacotherapy 37: 671-674 [Abstract] [Full Text]  
• Oscier, D. G., Gardiner, A. C., Mould, S. J., Glide, S., Davis, Z. A., Ibbotson, R. E., Corcoran, M. M., Chapman, R. M., Thomas, P. W., Copplestone, J. A., Orchard, J. A., Hamblin, T. J. (2002). Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100: 1177-1184 [Abstract] [Full Text]  
• Hamblin, T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z., Thomas, P. W., Stevenson, F. K., Oscier, D. G. (2002). CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99: 1023-1029 [Abstract] [Full Text]  
• Rai, K. R., Dohner, H., Keating, M. J., Montserrat, E. (2001). Chronic Lymphocytic Leukemia: Case-Based Session. ASH Education Book 2001: 140-156 [Abstract] [Full Text]